Chlorambucil
| Error creating thumbnail: File missing | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Elimination half-life | 1.5 hours |
| Excretion | N/A |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C14H19Cl2NO2 |
| Molar mass | 304.212 g/mol |
|
WikiDoc Resources for Chlorambucil |
|
Articles |
|---|
|
Most recent articles on Chlorambucil Most cited articles on Chlorambucil |
|
Media |
|
Powerpoint slides on Chlorambucil |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Chlorambucil at Clinical Trials.gov Clinical Trials on Chlorambucil at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Chlorambucil
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Chlorambucil Discussion groups on Chlorambucil Patient Handouts on Chlorambucil Directions to Hospitals Treating Chlorambucil Risk calculators and risk factors for Chlorambucil
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Chlorambucil |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
- For patient information, click here
Overview
Chlorambucil (marketed as Leukeran by GlaxoSmithKline) is a chemotherapy drug that has been mainly used in the treatment of chronic lymphocytic leukemia. It is a nitrogen mustard alkylating agent and can be given orally.
In the past, it has been used for treating some types of non-Hodgkin lymphoma, Waldenström macroglobulinemia, polycythemia vera, trophoblastic neoplasms, ovarian carcinoma. It also has been used as an immunosuppressive drug for various autoimmune and inflammatory conditions, e.g. nephrotic syndrome. Its current use is mainly for CLL as it is well tolerated by most patients, though this has been primarily replaced by fludarabine.[1]
Side Effects
The IARC has found strong evidence that chlorambucil is itself a cancer agent, and listed it as such in its list 1.
Myelosuppression (anemia, neutropenia, thrombocytopenia), or bone marrow suppression is the most commonly occurring side effect of chlorambucil. Withdrawn from the drug, this side effect may be reversible, but bone marrow failure can occur in rare cases.
Less commonly occurring side effects include:
- Gastrointestinal Distress (nausea, vomiting, diarrhea, and oral ulcerations).
- Central Nervous System: Seizures, tremors, muscular twitching, confusion, agitation, ataxia, and hallucinations.
- Skin reactions
- Hepatotoxicity
- Infertility
References
- ↑ Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA (2000). "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia". N Engl J Med. 343 (24): 1750–7. PMID 11114313.
External links
- Leukeran (manufacturer's website)
- Chlorambucil (patient information)
- MedlinePlus's Drug Information
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Chemotherapeutic agents